Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cartesian Therapeutics (RNAC) over the last 11 years, with Q3 2025 value amounting to $143.4 million.

  • Cartesian Therapeutics' Cash & Equivalents fell 3458.7% to $143.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.4 million, marking a year-over-year decrease of 3458.7%. This contributed to the annual value of $212.6 million for FY2024, which is 17643.64% up from last year.
  • As of Q3 2025, Cartesian Therapeutics' Cash & Equivalents stood at $143.4 million, which was down 3458.7% from $160.3 million recorded in Q2 2025.
  • Cartesian Therapeutics' 5-year Cash & Equivalents high stood at $219.2 million for Q3 2024, and its period low was $76.9 million during Q4 2023.
  • Its 5-year average for Cash & Equivalents is $129.0 million, with a median of $114.6 million in 2021.
  • As far as peak fluctuations go, Cartesian Therapeutics' Cash & Equivalents surged by 17643.64% in 2024, and later tumbled by 3458.7% in 2025.
  • Cartesian Therapeutics' Cash & Equivalents (Quarter) stood at $114.1 million in 2021, then decreased by 6.68% to $106.4 million in 2022, then fell by 27.74% to $76.9 million in 2023, then surged by 176.44% to $212.6 million in 2024, then plummeted by 32.56% to $143.4 million in 2025.
  • Its Cash & Equivalents was $143.4 million in Q3 2025, compared to $160.3 million in Q2 2025 and $180.4 million in Q1 2025.